E pstein-Barr virus (EBV) is a ubiquitous gamma herpes virus and has been etiologically associated with several disease conditions. It induces primarily subclinical infections or acute infectious mononucleosis (IM), which are generally self-limiting. EBV mainly infects B cells and multiplies in them, a process controlled by EBV-specific cytotoxic T-lymphocytes (CTL).
1
It is also known that EBV infects T and NK cells, the proliferation of which is probably uncontrollable by CTL, and leads to the development of hemophagocytic lymphohistiocytosis (EBV-HLH), chronic active EBV infection (CAEBV) or EBV-related lymphoma. The clinical features of these EBV-related diseases sometimes overlap with high mortality and morbidity except for IM.
2
The distinct manifestations of IM, HLH and CAEBV are thought to be affected by the host's different immune response to EBV, especially by cytokine production. The levels of interleukin (IL)-1α, IL-2, IL-6, and interferon (IFN)-γ have been reported to be elevated in the serum of patients with IM. 3, 4 In EBV-HLH, serum levels of IFN-γ and soluble IL-2 receptor (sIL-2R) are especially high.
5,6
Patients with CAEBV were found to have abnormally high levels of circulating human IL-10 as well as EBVencoded IL-10 (vIL-10), which may contribute to the pathogenesis of CAEBV by inhibiting host immunity.
7
There is also increasing evidence indicating that cytokine gene polymorphisms, such as those of the IL-10 8 and IL-1α 9 genes, have an impact on susceptibility to EBV infection. These studies focused on whether resistance to EBV infection (EBV seronegativity) was influenced by the polymorphic IL-10 or IL-1β gene. By contrast, in this study we were interested to see whether, among an EBV-seropositive population, polymorphisms of these cytokine genes determine the development of distinct features between the group with subclinical infection (seropositive control, no clinical manifestation) and groups with clinical manifestations of EBV infection, such as IM, HLH and CAEBV. Regarding the development of EBV-lymphoproliferative disease (LPD) in immuno-deficient states, Dierksheide et al. 10 demonstrated that IFN-γ gene polymorphisms played a role in the high prevalence of LPD using human peripheral blood in SCID mice; however, no cytokine gene polymorphisms have so far been studied among patients with EBV-related hematologic diseases.
We, therefore, compared the influence of cytokine gene polymorphisms in three EBV-related diseases, IM, EBV-HLH and CAEBV, against that in EBV-seropositive healthy controls. Briefly, patients had to be positive for the EBV genome in peripheral blood, bone marrow or other tissues, and/or positive for VCA-IgG in association with clinical symptoms compatible with HLH, such as persistent high fever, cytopenia, liver dysfunction and coagulopathy. CAEBV was diagnosed according to the criteria published by the Japanese Association for Research on Epstein-Barr Virus and Related Diseases. 13 Briefly, a patient was diagnosed as having CAEBV in the presence of (i) EBV-related illness continuing for more than 6 months with symptoms including fever, persistent hepatitis, extensive lymphadenopathy, hepatosplenomegaly, pancytopenia, uveitis, interstitial pneumonia, hydroa vacciniforme, or hypersensitivity to mosquito bites, (ii) increased quantities of EBV gene in either affected tissues or peripheral blood, and (iii) no evidence of any prior immunologic abnormalities or of any other recent infection, such as human immunodeficiency virus, that might explain the condition. Healthy immunocompetent adults with an elevated titer of VCA-IgG with no previous history of IM, HLH or CAEBV were used as controls.
Design and Methods
Genomic DNA was extracted from peripheral blood using a QIAamp blood kit (Quiagen, Hilden, Germany) following the protocol recommended by the manufacturer, and 100 µL DNA were used for polymorphism studies. Gene polymorphism typing was performed by polymerase chain reaction with a sequence-specific primer (PCR-SSP) using a commercially available cytokine genotyping kit (PEL-FREEZ, USA). This kit contains specific primers to detect the following bial- 
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Statistical analysis was performed with Fisher's exact tests to compare the frequencies of cytokine alleles, haplotypes and genotypes among patients with the three types of EBV-related diseases and the controls.
Results Figure 1 shows a representative electrophoresis pattern of loading PCR-SSP products. The frequency of TGF-β1 codon 10 C allele was significantly higher in patients with EBV-related diseases (IM + HLH + CAEBV) than in controls (p<0.001); a significant difference was also observed between patients with IM or HLH and controls (43/ Table 2) . No statistically significant differences were found in other genes including IL-1R, IL-1RA, IL-4Rα, IL-12, IFN-γ, TNF-α, IL-2 and IL-6 (data not shown).
Discussion
Our study showed that the TGF-β1 gene polymorphism differed significantly between patients with EBV-related diseases and controls; the frequency of TGF-β1 codon 10 C allele was significantly higher in patients with IM or EBV-HLH than in controls. As regards other genes, the frequency of the IL-1α -889 C allele was lower in patients with IM than in controls.
TGF-β is member of a highly pleiotropic family of growth factors involved in the regulation of numerous physiologic processes in a variety of cell types. It plays a role as a switch factor in immune suppression 14 and promotes the proliferation of cells of EBV-positive Burkitt's lymphoma cell lines as well as EBV-infected B cells.
15 TGF-β1 was found to be produced in the tonsillar tissues of patients with IM, 16 elevated in EBV-associated nasopharyngeal carcinoma, 17 and its dominant expression was demonstrated in activated T cells of CAEBV patients. 18 These previous observations show some link between high levels of TGF-β1 and the pathogenesis of EBV-related diseases. The codon 10 is an important site for the regulation of TGF-β1 gene expression and the C allele at this site was reported to be linked to high levels of TGF-β1 mRNA and its protein. 19, 20 In fact, Suthanthiran et al. reported that both mRNA and protein levels of TGF-β1 in the population were higher among subjects genotyped as C/C or C/T at codon 10 compared with those genotyped as T/T. 19 Thus, the polymorphism causing an amino acid substitution from leucine to proline might influence TGF-β1 protein secretion, which up-regulates its own transcription via AP-1 sites located in its promoter. 19 Since our data also showed that frequency of the TGF-β1 gene codon 10 C allele was high in patients with IM and HLH, presumably, the polymorphism (C allele) at codon 10 of TGF-β1 suppresses the immune reaction to EBV that occurs at first exposure to the virus, thus failing to limit the infection at a subclinical level and enabling the development of clinically definable EBVrelated diseases.
On the other hand, IL-1 is the prototype of the proinflammatory cytokines, which induce the expression of a variety of genes and the synthesis of several proteins that, in turn, induce acute and chronic inflammatory changes in response to injury and infection, and affects nearly every tissue and organ system. 21 IL-1 directly influences B cells by inducing their differentiation, growth and the synthesis of immunoglobulin. IL-1 also activates T cells and is involved in T-cell proliferation. It has been reported that serum levels of IL-1α were high in patients with IM. 3 The expression of IL-1β was high in the tonsils of IM patients, and that of IL-1α was high in epithelial cells. 22 By contrast, no significant increases of serum IL-1α and β levels were found in HLH patients. 23 We previously noted that serum levels of IL-1 were high in a limited number of patients with HLH in spite of extremely high levels of IFN-γ, sIL-2R, IL-6 and TNF in many such patients.
24,25
Higher IL-α protein levels were associated with the T allele at -889, but not with the C allele in the promoter region of the IL-1α gene. 26, 27 Our findings that the frequency of the IL-1α -889 C allele was lower in IM and relatively higher in EBV-HLH patients than in con- 
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trols are probably compatible with previous observations, 3,23-25 suggesting excessive secretion of IL-1 in IM patients, which may play a role in the prompt eradication of primary EBV infection. On the other hand, insufficient production of IL-1 could lead to failure of the immune response and to sequential progression of the primary infection into HLH.
With the use of diagnostic criteria, IM, HLH and CAEBV can be differentiated into distinct disease entities, although some overlapping of the clinical features does occur; however, to date, no clear mechanism has been clarified to explain the differential development of these subtypes of EBV-related hematologic diseases. Interestingly, high EBV copy numbers in the blood, suggesting EBV reactivation in recipients of allogeneic hematopoietic stem cell transplantation, were found to be prevalent among patients with a certain IFN-γ genotype. 33 Although previous reports also showed that serum levels of EBV copy numbers may differentiate the clinical features of IM and HLH, 34, 35 in our study, we were unable to demonstrate a difference in IFN-γ polymorphisms among patients with IM, HLH and CAEBV. Apart from cytokine gene polymorphisms, Zaitsu et al. 36 previously identified a higher prevalence of the QPY haplotype of granzyme B in patients with EBV-HLH than in either patients with IM or healthy controls. Most of the reported cases of CAEBV have occurred in Japan and the pathophysiology of this condition has been clarified. 37 However, it remains unclear how the status of CAEBV develops; does it occur as a progression from IM or HLH, or through a totally independent and different mechanism? To our surprise, in this study, the frequencies of both TGF-β1 and IL-1α gene polymorphisms in CAEBV patients were different from those in IM or HLH patients, suggesting the latter mechanism may be involved.
In summary, we demonstrated that the polymorphism of TGF-β1 at codon 10 is associated with the development of EBV-related hematologic diseases, such as IM or HLH, among Japanese subjects. According to some earlier studies on various diseases, the frequencies of polymorphisms in the TGF-β1 and IL-1α genes were not different between Caucasian and Asian ethnic groups. [28] [29] [30] [31] [32] However, no data are available for patients with EBV-related diseases. A future, larger study is required to determine whether our findings on EBV-related diseases are specific to Asian/Japanese patients or are common to patients of all ethnic groups. 
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